The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies

Abstract The increase in the number of therapeutic alternatives for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM) patients has widened the clinical scenario, leading to a level of complexity that no algorithm has been able to cover up to date. At present, this complexity incre...

Full description

Bibliographic Details
Main Authors: José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso, Juan-José Lahuerta
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Biomarker Research
Subjects:
Multiple myeloma
Monoclonal antibodies
Proteasome inhibitors
Immunomodulatory drugs
New agents
Relapsed
Online Access:https://doi.org/10.1186/s40364-021-00344-2

Internet

https://doi.org/10.1186/s40364-021-00344-2

Similar Items